Pfizer's Viagra market share in China challenged by Guangzhou Baiyunshan's 'golden spear'

Jin'ge (Chinese for "golden spear") from China's Guangzhou Baiyunshan is said to be on track to eclipse sales of Pfizer's ($PFE) Viagra in China in a few years with a price that is 60% less than the branded erectile dysfunction drug. The company is also said to be looking at taking the copy international. Before Jin'ge hit the market last year, Viagra reportedly had 60% of the market share and Eli Lilly's ($LLY) Cialis held 34.6%, FiercePharmaAsia reports.

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.